Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index
杜拉鲁肽每周一次治疗基线体重指数较低的成年2型糖尿病患者的疗效和安全性
Yongquan Shi
Department of Endocrinology, Changzheng Hospital, Naval Medical University, Shanghai, China
Search for more papers by this authorSiying Liu
Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China
Search for more papers by this authorJiankun Zhu
Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China
Search for more papers by this authorCorresponding Author
Tianpei Hong
Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China
Correspondence
Tianpei Hong, Department of Endocrinology and Metabolism, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing 100191, China.
Email: [email protected]
Search for more papers by this authorYongquan Shi
Department of Endocrinology, Changzheng Hospital, Naval Medical University, Shanghai, China
Search for more papers by this authorSiying Liu
Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China
Search for more papers by this authorJiankun Zhu
Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China
Search for more papers by this authorCorresponding Author
Tianpei Hong
Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China
Correspondence
Tianpei Hong, Department of Endocrinology and Metabolism, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing 100191, China.
Email: [email protected]
Search for more papers by this authorGraphical Abstract
Highlights
- In Chinese patients with type 2 diabetes (T2D) and body mass index (BMI) <25 kg/m2, dulaglutide demonstrated great improvements in glycemic control with mild body weight reduction and low hypoglycemia risk.
- The results indicate that dulaglutide is effective and safe in patients with T2D and lower BMI; therefore, BMI should not be a consideration when dulaglutide is prescribed to Chinese patients with T2D.
Supporting Information
| Filename | Description |
|---|---|
| jdb13147-sup-0001-FigureS1.pngPNG image, 1.2 MB | Figure S1. Changes in HbA1c (Supp 1A) and body weight (Supp 1B) from baseline at week 26 by different baseline BMI categories (BMI <24; 24 ≤ BMI <28; 28 ≤ BMI <30; BMI ≥30 kg/m2). Abbreviations: BMI, body mass index; DU, dulaglutide; HbA1c, glycated hemoglobin; n, number of patients in each category. |
| jdb13147-sup-0002-TableS1.docxWord 2007 document , 42.3 KB | Table S1. Incidence of hypoglycemia and gastrointestinal adverse events through 26 weeks |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Gentilella R, Sesti G, Vazquez L, et al. Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index. Diabetes Obes Metab. 2019; 21: 2660-2666.
- 2Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-likepeptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014; 16: 900-909.
- 3Zhang F, Tang L, Zhang Y, Lu Q, Tong N. Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials. Sci Rep. 2017; 7:15997. https://doi.org/10.1038/s41598-017-16018-9.
- 4Gallwitz B, Dagogo-Jack S, Thieu V, et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018; 20: 409-418.
- 5Chen YH, Huang CN, Cho YM, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in east-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes Obes Metab. 2018; 20: 2121-2130.
- 6Wang W, Nevárez L, Filippova E, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: a 52-week open-label, randomized phase III trial. Diabetes Obes Metab. 2019; 21: 234-243.
- 7Chen C, Lu FC, Department of Disease Control Ministry of Health, PR China. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci. 2004; 17: 1-36.
- 8 World Health Organization. Obesity and Overweight [Internet]. Geneva: WHO; 2020 https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
- 9Yu M, Yuan GY, Zhang B, Wu HY, Lv XF. Efficacy and safety of dulaglutide by baseline HbA1c in Chinese patients with type 2 diabetes: a post hoc analysis. Diabetes Ther. 2020; 11: 1147-1159.
- 10Hamano K, Nishiyama H, Matsui A, Sato M, Takeuchi M. Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment. Endocr J. 2017; 64: 449-456.
- 11Montanya E, Fonseca V, Colagiuri S, et al. Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme. Diabetes Obes Metab. 2016; 18: 707-710.
- 12Wolffenbuttel BH, Van Gaal L, Duran-Garcia S, Han J. Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab. 2016; 18: 829-833.
- 13Shalev A, Holst JJ, Keller U. Effects of glucagon-like peptide 1 (7–36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest. 1997; 27: 10-16.
- 14Naslund E, Gutniak M, Skogar S, Rössner S, Hellström PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr. 1998; 68: 525-530.
- 15Carls GS, Tan R, Zhu JY, et al. Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence. Obes Sci Pract. 2017; 3: 342-351.
- 16Conget I, Mauricio D, Ortega R, Detournay B, CHADIG Study Investigators. Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG study): a cross-sectional multicentre study in Spain. BMJ Open. 2016; 6:e010197.
Citing Literature
